About MEDEA Biopharma
MEDEA Biopharma is a Healthcare company based in Ludwigshafen Am Rhein (Germany) founded in 2022 by Giorgi Khubua, Rudiger Trojok, Alexander Skripnik, and Elene Kakabadze. It operates as a therapeutics for infectious diseases are developed using bacteriophage compounds. Its chief executive is Rudiger Trojok. MEDEA Biopharma offers products and services including Bacteriophage Antimicrobials. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is MEDEA BIOPHARMA GMBH. Its competitors include Insmed, BiomX, Affinivax, Adaptive Phage Therapeutics and Eligo Bioscience and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
MEDEA Biopharma was established in 2022 in Ludwigshafen Am Rhein, Germany, within the biopharmaceutical sector. Therapeutics targeting infectious diseases are developed, with antimicrobial compounds derived from bacteriophages employed to identify and eradicate harmful bacteria. These solutions are applied across multiple industries, including healthcare and related fields, to address bacterial challenges effectively. Operations focus on innovative phage-based technologies for therapeutic applications.
- Headquarters Ludwigshafen Am Rhein, Germany
- Founders Giorgi Khubua, Rudiger Trojok, Alexander Skripnik, Elene Kakabadze
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website medea-bio.com
- Social LinkedIn
- Legal Name Medea Biopharma Gmbh
- Latest Funding Round$26.92K (USD), Grant
May 2023
- Investors
Products & Services of MEDEA Biopharma
MEDEA Biopharma offers a comprehensive portfolio of products and services, including Bacteriophage Antimicrobials.
Targets and eliminates harmful bacteria using phages for industry applications.
Funding Insights of MEDEA Biopharma
- Total Rounds 1
- Last Round Grant — $26,919
- First Round $26,919
(May 2023)
- Investors Count 1
All 1 funding rounds of MEDEA Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $26,919 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in MEDEA Biopharma
MEDEA Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TechFounders.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
TechFounders is engaged in fostering partnerships between corporates and startups. | – | techfounders.com | - |
Investor details for MEDEA Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MEDEA Biopharma
4 people are tracked at MEDEA Biopharma (4 in leadership).
| Name | Role | Group |
|---|---|---|
Giorgi Khubua | Co-Founder & MD | Leadership |
Rudiger Trojok | Co-Founder & CEO | Leadership |
Alexander Skripnik | Co-Founder | Leadership |
Elene Kakabadze | Co-Founder | Leadership |
Complete people profiles for MEDEA Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MEDEA Biopharma
2 dated milestones of MEDEA Biopharma across 1 years, from founding to its latest funding, stage changes and deals.
- Founded MEDEA Biopharma is founded.
- Funding First funding round of $27K.
Competitors of MEDEA Biopharma
MEDEA Biopharma has 9 listed competitors in our database, 7 of them funded. They include Insmed, BiomX, Affinivax, Adaptive Phage Therapeutics and Eligo Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| biomx.com | 2015 | Ness Ziona, Israel | $56M | – | Microbiome therapeutics are developed for dysbiosis-linked diseases. | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| maatpharma.com | 2014 | Lyon, France | $42.3M | – | Microbiome therapies are developed for treating intestinal dysbiosis diseases. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI |
Detailed competitors of MEDEA Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as MEDEA Biopharma (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MEDEA Biopharma
MEDEA Biopharma was founded in 2022 and raised its 1st funding round 1 year after it was founded.
MEDEA Biopharma is headquartered in Ludwigshafen Am Rhein, Germany. It is registered at Ludwigshafen Am Rhein, Rheinland-pfalz, Germany.
Rudiger Trojok is the current CEO of MEDEA Biopharma. They have also founded this company.
MEDEA Biopharma was established in 2022 in Ludwigshafen Am Rhein, Germany, within the biopharmaceutical sector. Therapeutics targeting infectious diseases are developed, with antimicrobial compounds derived from bacteriophages employed to identify and eradicate harmful bacteria. These solutions are applied across multiple industries, including healthcare and related fields, to address bacterial challenges effectively. Operations focus on innovative phage-based technologies for therapeutic applications.
MEDEA Biopharma's top competitors include Aridis Pharma, Insmed and MaaT Pharma.
MEDEA Biopharma offers Bacteriophage Antimicrobials.
MEDEA Biopharma has 1 investor. Key investors include TechFounders.
MEDEA Biopharma operates through Medea Biopharma Gmbh.